Key result
Suspending antiplatelet therapy for procedures demands an individualized balance between bleeding and thrombotic risks.
Why the study?
Increasing procedural interventions requiring antiplatelet suspension necessitate balancing thrombotic and bleeding risks through an understanding of indications, complications, and management strategies.
Suspending antiplatelet therapy for surgical procedures requires an individualized, multidisciplinary approach to balance the risks of bleeding and thrombosis.
Answers are grounded in this paper and cite their sources.
Management of antiplatelet interruption for procedures lacks high-quality evidence; leaves open optimal periprocedural strategies balancing ischemic and bleeding risks.
Antiplatelet therapy is increasingly common, especially among patients with ischemic heart disease or atrial fibrillation. With the rising number of individuals undergoing anticoagulation treatment, often for conditions like atrial fibrillation, and the increased use of antiplatelet drugs for atherosclerotic disease prevention, the necessity for procedural interventions that require the suspension of these therapies has surged. The decision to interrupt antiplatelet treatment becomes crucial in such scenarios, balancing the risks of thrombotic events and bleeding complications. Implementing appropriate strategies demands a comprehensive understanding of the indications, associated complications, and optimal management of this therapeutic interruption. This review aims to consolidate current knowledge and guidelines, providing insights into the theoretical framework, indications for suspension, potential complications, and practical considerations in managing the suspension of antiplatelet therapy in clinical scenarios related to ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Mora et al. (2023) conducted a review in Ischemic heart disease. Suspension of antiplatelet therapy was evaluated. Suspending antiplatelet therapy for surgical or interventional procedures requires a delicate, individualized balance between the risk of bleeding complications and the risk of thrombotic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: